The American Lung Association has called for a halt to the sale of all tobacco products at all retailers with pharmacies.
Formulary Watch
Latest News
All News
Advertisement
Because there was no approved medication treatment for idiopathic pulmonary fibrosis (IPF) until mid-October, 2014, physicians primarily focused on non-pharmacological treatments to help patients improve. Even with FDA’s approval of nintedanib (Ofev) and pirfenidone (Esbriet), physicians will continue to recommend certain therapies that generally ease symptoms and improve patients’ quality of life.
While physicians laud FDA’s approval of nintedanib (Ofev) and pirfenidone (Esbriet) for treating idiopathic pulmonary fibrosis (IPF)-the first approved medications to treat the disease in the United Sates-they don’t know how to use them.
Antiviral drug oseltamavir (Tamiflu, Roche) shortens the length of flu symptoms by about 1 day, and reduces respiratory infections that sometimes develop by 44%, according to a study published in The Lancet.
The Patient-Centered Outcomes Research Institute (PCORI) has issued 6 new funding announcements offering up to $138 million in support for studies comparing how well different approaches to care work for patients given their particular circumstances and concerns.
FDA has expanded the approved use of ranibizumab (Lucentis, Genentech) to treat diabetic retinopathy in patients with diabetic macular edema (DME).
It is possible to get treatments to stroke patients even before they arrive at a hospital, according to a study published in the New England Journal of Medicine.
Managed care and hospital decision-makers are in a key position to “move the needle” at the system level on improving adult immunization coverage rates in the United States.
After six years on the job, FDA commissioner Margaret Hamburg, MD, is resigning from her position. Her tenure has ushered in personalized medicine and faster approval of several drug classes.
Non-medication strategies were effective in hospital patients with delirium, according a new study published in the February 2 edition of the JAMA Internal Medicine.
Advertisement
FDA has approved olopatadine hydrochloride ophthalmic solution (Pazeo, Alcon, a division of Novartis) 0.7% for the treatment of ocular itch relief related to eye allergies.
Ibrance is a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which complex with a regulatory protein, called cyclin, to control cancer cell cycling. The FDA has approved it for use in the treatment of metastatic breast cancer.
FDA approved TissuGlu (Cohera Medical Inc.), the first tissue adhesive approved for internal use.
Diabetic non-smokers taking metformin have a lower lung cancer risk compared with those who do not take metformin, according to a study published in Cancer Prevention Research.
Given the spending growth projections for biologics, successful managed care organizations must find a way to ensure appropriate adoption of biosimilars, according to a study published in Health Affairs’ February issue.
Many patients hospitalized with severe heart failure are receiving potentially harmful treatment with intravenous fluids, according to a Yale-led study, published in the Journal of the American College of Cardiology (JACC): Heart Failure
FDA has approved a new formulation of Zohydro ER (Zogenix) with BeadTek.
The first-in-class combined medication for improving glycemic control in adults with type 2 diabetes has been approved by FDA.
FDA actions in brief, priority review, breakthrough designations, orphan drug designations
More than one-third of reproductive-aged women enrolled in Medicaid, and more than a quarter of those with private insurance, filled a prescription for an opioid pain medication each year during 2008 to 2012, according to a recent report in Morbidity and Mortality Weekly Report (MMWR).
FDA approved lisdexamfetamine dimesylate (Vyvanse, Shire) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week.
Statin treatment reduces the risk of cardiovascular disease in women, according to a large international study, published in The Lancet.
Hydrocodone bitartrate (Hysingla ER, Purdue Pharma) extended-release tablets CII is now commercially available.
FDA has approved the antiretroviral Prezcobix (darunavir 800 mg/cobicistat 150 mg, Janssen Therapeutics) for the treatment of human immunodeficiency virus 1 (HIV-1).
FDA has approved expanded use of ibrutinib for the treatment of Waldenstroms Macroglobulinemia.
FDA's process for approving drugs and devices is speeding up, according to a PricewaterhouseCoopers (PwC) Health Research Institute report.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New drug class shows promise for geographic atrophy
2
Global MS analysis links disability burden to rising economic strain
3
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5
